SOGC’s medical abortion training program, 2024Link: sogc-training NAF Canada’s medication abortion training for primary care providers, 2023Link: nafc-training Case-based quizzes on medication abortion for pharmacistsLink: pharmacy5in5

A road map for all pharmacists, 2023Canadian Pharmacists Association & The CART Access ProjectLink: [cpha-roadmap](CPHA2) Pharmacist resource guide for medical abortion, 2018Judith Soon & Nevena Rebic; […]

Below is a general guide of the steps to be taken when initiating medication abortion (MA) services at your pharmacy. Some of these may not […]

Prescribers will provide clinical assessments prior to prescribing MIFE / MISO. With the new guideline by SOGC for the provision of medical abortion via telemedicine (MA), prescribers […]

MIFE taken orally shows non-linear pharmacokinetics. It is rapidly absorbed and distributed, reaching peak concentrations after 0.75 hours. It is 94-99% plasma-bound and is metabolized […]

MIFE is metabolized by CYP3A4 and is also an irreversible competitive inhibitor of CYP3A4 and, to a lesser extent, of CYPs 1A, 2B, 2D6 and […]

Patients are required to have a follow-up consultation with prescribers. A follow-up with dispensers is optional and can take place 2 – 3 days after MISO administration. […]

Prior to arriving at the pharmacy for MIFE / MISO, people seeking abortion, hereinafter called “patients”, will already have had a conversation with prescribers about medication abortion […]

Through a partnership with the Yukon Hospital Corporation, the Government of Yukon is now offering universal coverage of Mifegymiso. This partnership ensures that Yukoners have […]

Saskatchewan provides 100% coverage for Mifegymiso for residents eligible under the Saskatchewan Drug Plan. Claims may be submitted electronically to the Saskatchewan Drug Plan. Link: […]